Seeking Alpha

Novavax (NVAX) provides a positive report from the Phase I trial of what would be the first...

Novavax (NVAX) provides a positive report from the Phase I trial of what would be the first vaccine for respiratory syncytial virus (RSV), which causes pneumonia, as well as bronchiolitis in babies. Shares -3.5% but they've been rising since the middle of June. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs